Use of Ebola Vaccine: Expansion of Recommendations of the Advisory Committee on Immunization Practices To Include Two Additional Populations - United States, 2021 [0.03%]
关于使用埃博拉疫苗的情况：美国免疫实践咨询委员会推荐范围扩大至两类新增群体——2021年
Jason H Malenfant,Allison Joyce,Mary J Choi et al.
Jason H Malenfant et al.
On December 19, 2019, the Food and Drug Administration (FDA) approved rVSVΔG-ZEBOV-GP Ebola vaccine (ERVEBO, Merck) for the prevention of Ebola virus disease (EVD) caused by infection with Ebola virus, species Zaire ebolavirus, in adults a...
Interim Guidance: 4-Month Rifapentine-Moxifloxacin Regimen for the Treatment of Drug-Susceptible Pulmonary Tuberculosis - United States, 2022 [0.03%]
2022年美国耐药肺结核治疗的 interim 指南：4个月利福平-莫西沙星疗法
Wendy Carr,Ekaterina Kurbatova,Angela Starks et al.
Wendy Carr et al.
On May 5, 2021, CDC's Tuberculosis Trials Consortium and the National Institutes of Health (NIH)-sponsored AIDS Clinical Trials Group (ACTG) published results from a randomized controlled trial indicating that a 4-month regimen containing r...
Antigen Test Positivity After COVID-19 Isolation - Yukon-Kuskokwim Delta Region, Alaska, January-February 2022 [0.03%]
2022年1—2月阿拉斯加尤皮克河流域地区新冠肺炎隔离后抗原检测阳性情况
Brian Lefferts,Ian Blake,Dana Bruden et al.
Brian Lefferts et al.
Isolation is recommended during acute infection with SARS-CoV-2, the virus that causes COVID-19, but the duration of infectiousness varies among individual persons. Rapid antigen test results have been correlated with detection of viable vi...
Pediatric Emergency Department Visits Before and During the COVID-19 Pandemic - United States, January 2019-January 2022 [0.03%]
2019年1月—2022年1月美国新冠肺炎大流行前后的儿科急诊就诊情况
Lakshmi Radhakrishnan,Kelly Carey,Kathleen P Hartnett et al.
Lakshmi Radhakrishnan et al.
Emergency departments (EDs) in the United States remain a frontline resource for pediatric health care emergencies during the COVID-19 pandemic; however, patterns of health-seeking behavior have changed during the pandemic (1,2). CDC examin...
Advisory Committee on Immunization Practices Recommended Immunization Schedule for Children and Adolescents Aged 18 Years or Younger - United States, 2022 [0.03%]
2022年美国儿童及青少年（18岁及以下）接种推荐一览表
A Patricia Wodi,Neil Murthy,Henry Bernstein et al.
A Patricia Wodi et al.
At its November 2021 meeting, the Advisory Committee on Immunization Practices* (ACIP) approved the Recommended Child and Adolescent Immunization Schedule for Ages 18 Years or Younger-United States, 2022. The 2022 child and adolescent immun...
Advisory Committee on Immunization Practices Recommended Immunization Schedule for Adults Aged 19 Years or Older - United States, 2022 [0.03%]
2022年美国19岁及以上成人免疫接种推荐概要
Neil Murthy,A Patricia Wodi,Henry Bernstein et al.
Neil Murthy et al.
At its November 2021 meeting, the Advisory Committee on Immunization Practices* (ACIP) approved the Recommended Adult Immunization Schedule for Ages 19 Years or Older, United States, 2022. The 2022 adult immunization schedule summarizes ACI...
Safety Monitoring of COVID-19 Vaccine Booster Doses Among Adults - United States, September 22, 2021-February 6, 2022 [0.03%]
2021年9月22日至2022年2月6日美国成年人新冠疫苗加强针的监测数据——安全性监视报告
Anne M Hause,James Baggs,Paige Marquez et al.
Anne M Hause et al.
During September 22, 2021-February 6, 2022, approximately 82.6 million U.S. residents aged ≥18 years received a COVID-19 vaccine booster dose.* The Food and Drug Administration (FDA) has authorized a booster dose of either the same product...
Waning 2-Dose and 3-Dose Effectiveness of mRNA Vaccines Against COVID-19-Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron Variant Predominance - VISION Network, 10 States, August 2021-January 2022 [0.03%]
关于新冠mRNA疫苗在Delta和Omicron变异株流行期间对成人急诊科就诊、住院等效果的下降——来自美国10个州的VISION网络，2021年8月-2022年1月
Jill M Ferdinands,Suchitra Rao,Brian E Dixon et al.
Jill M Ferdinands et al.
CDC recommends that all persons aged ≥12 years receive a booster dose of COVID-19 mRNA vaccine ≥5 months after completion of a primary mRNA vaccination series and that immunocompromised persons receive a third primary dose.* Waning of vac...